ASCO26: Solid tumour data readouts outline Merck & Co's oncology prowess - Pharmaceutical Technology

Keytruda continues to shine in solid tumours, and other Merck & Co assets signal designs to address Keytruda's upcoming exclusivity loss. Keytruda continues to shine in solid tumours, and other Merck & Co assets signal designs to address Keytruda's upcoming exclusivity loss. The release of data with assets from Merck & Co, AstraZeneca and Eisai for the treatment of solid tumours at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting signal the latest in developments in research and treatment strategies. Image credit: [PeopleImages]/Shutterstock.com The American Society of Clinical Oncology (ASCO) 2026 Annual Meeting saw the presentation of several…

Source: Pharmaceutical Technology